Form 4: Arcutis Biotherapeutics Executive Acquires Shares and Stock Options

Larry Todd Edwards, Executive Vice President and Chief Commercial Officer of Arcutis Biotherapeutics, reports acquisition of shares and stock options.

Summary

• On February 28, 2025, Larry Todd Edwards acquired 38,000 shares of common stock and 17,000 shares of common stock.
• He also acquired options to purchase 99,000 shares and 43,000 shares of common stock at an exercise price of $13.69.
• The shares are restricted stock units (RSUs) that vest 25% annually starting March 1, 2026.
• The stock options vest 1/48th monthly starting March 1, 2025, and will be fully vested on the fourth anniversary.
• Following these transactions, Edwards beneficially owns 190,555 shares of common stock and options to purchase 142,000 shares.
• The report was filed on March 4, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option acquisitions by an executive. The acquisition itself could be interpreted as a slightly positive signal, but the filing is primarily informational.

Positives

• The acquisition of shares and options by a key executive could be seen as a positive sign of confidence in the company's future prospects.

Future Outlook

The RSUs vest annually starting March 1, 2026, and the stock options vest monthly starting March 1, 2025, subject to continued service.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like executives, buy or sell their company's stock. It provides transparency to the market about insider activity.

Stakeholder Impact

• The transactions could have a minor positive impact on shareholder sentiment.

Key Dates